1. Jubilant Life jumps 8% on USFDA nod for hypertension tablets

Jubilant Life jumps 8% on USFDA nod for hypertension tablets

Jubilant Life Sciences stock today surged nearly 8 per cent after it received final approval from the US health regulator to sell tablets used in the treatment of hypertension in the American market.

By: | New Delhi | Published: August 25, 2016 2:33 PM
In a BSE filing, the company said: "It has received abbreviated new drug application (ANDA) final approval for Felodipine Extended-Release Tablets USP, 2.5 mg, 5 mg, and 10 mg, the generic version of Plendil tablets of AstraZeneca." (Source: IE) In a BSE filing, the company said: “It has received abbreviated new drug application (ANDA) final approval for Felodipine Extended-Release Tablets USP, 2.5 mg, 5 mg, and 10 mg, the generic version of Plendil tablets of AstraZeneca.” (Source: IE)

Jubilant Life Sciences stock today surged nearly 8 per cent after it received final approval from the US health regulator to sell tablets used in the treatment of hypertension in the American market.

The scrip gained 7.81 per cent to Rs 546.70 – its 52-week high – on BSE.

On NSE, it jumped 7.74 per cent to touch 1-year high of Rs 546.90.

In a BSE filing, the company said: “It has received abbreviated new drug application (ANDA) final approval for Felodipine Extended-Release Tablets USP, 2.5 mg, 5 mg, and 10 mg, the generic version of Plendil tablets of AstraZeneca.”

As on June 30, 2016, Jubilant Life Sciences had a total of 770 filings for Oral Solids, of which 578 have been approved in various regions globally.

  1. No Comments.

Go to Top